

(51) International Patent Classification:
A61K 35/74 (2015.01) A61K 39/08 (2006.01)

(21) International Application Number:
PCT/US2024/019341

(22) International Filing Date:
11 March 2024 (11.03.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/451,442 10 March 2023 (10.03.2023) US
63/469,080 26 May 2023 (26.05.2023) US

(71) Applicant: KANVAS BIOSCIENCES, INC. [US/US]; 1 Deer Park Drive, Suite G-5, Monmouth Junction, NJ 08852 (US).

(72) Inventors: SWEN, Robert, Lee; c/o KANVAS BIOSCIENCES, INC., 1 Deer Park Drive, Suite G-5, Monmouth Junction, NJ 08852 (US). HAMILTON, Joshua, J.; c/o KANVAS BIOSCIENCES, INC., 1 Deer Park Drive, Suite G-5, Monmouth Junction, NJ 08852 (US). BERLEMAN, James; c/o KANVAS BIOSCIENCES, INC., 1 Deer

Park Drive, Suite G-5, Monmouth Junction, NJ 08852 (US). JACOBY, Kyle; c/o KANVAS BIOSCIENCES, INC., 1 Deer Park Drive, Suite G-5, Monmouth Junction, NJ 08852 (US). GIGLAR, Ariana, M.; c/o KANVAS BIOSCIENCES, INC., 1 Deer Park Drive, Suite G-5, Monmouth Junction, NJ 08852 (US). PARMAR, Anupreet; c/o KANVAS BIOSCIENCES, INC., 1 Deer Park Drive, Suite G-5, Monmouth Junction, NJ 08852 (US). BHALLA, Aditya; c/o KANVAS BIOSCIENCES, INC., 1 Deer Park Drive, Suite G-5, Monmouth Junction, NJ 08852 (US). KUMAR, Pawan; c/o KANVAS BIOSCIENCES, INC., 1 Deer Park Drive, Suite G-5, Monmouth Junction, NJ 08852 (US).

(74) Agent: LENDARIS, Steven, P. et al.; BAKER BOTTS L.L.P., 30 Rockefeller Plaza, New York, NY 10112-4498 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

(54) Title: MICROBIAL CONSORTIA




Figure 1A

(57) Abstract: The present disclosure provides microbial consortia, and methods of making and using the same, comprising a complete microbiome replacement capable of stable engraftment in the gastrointestinal tract for the treatment of IBD, ulcerative colitis, and Crohn's disease.

[Continued on next page]

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*